跳至主要内容
临床试验/NCT06772220
NCT06772220招募中不适用

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

Oregon Health and Science University1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2024年3月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
150
试验地点
1
主要终点
Hyperhomocysteinemia and B vitamin deficiency

研究概览

简要总结

This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
  • •Currently treated with levodopa at a minimum dose of 300 mg/day
  • •Montreal Cognitive Assessment (MOCA) ≥15
  • •Demonstrated capacity to provide informed consent.
  • •40-90 years of age
  • •Estimated glomerular filtration rate ≥60
  • •Absence of uncontrolled hypertension in medical history
  • •Absence of insulin use

排除标准

  • 未提供

研究组 & 干预措施

No vitamins

No Intervention

No vitamin intervention.

B vitamin regimen

Experimental

Daily doses of 1mg folic acid, 25mg vitamin B6, and 1,000 ug vitamin B12.

干预措施: Vitamin B12 (Dietary Supplement)

B vitamin regimen

Experimental

Daily doses of 1mg folic acid, 25mg vitamin B6, and 1,000 ug vitamin B12.

干预措施: Folic Acid 1 MG (Dietary Supplement)

B vitamin regimen

Experimental

Daily doses of 1mg folic acid, 25mg vitamin B6, and 1,000 ug vitamin B12.

干预措施: Vitamin B6 25 MG (Dietary Supplement)

结局指标

主要结局

Hyperhomocysteinemia and B vitamin deficiency

时间窗: baseline measurement

Plasma vitamin B12 in subjects with vs without hyperhomocysteinemia

次要结局

  • Hyperhomocysteinemia and cognitive assessments(From enrollment to the end of treatment at 3 months)
  • Hyperhomocysteinemia and measurement of neurofilament light in plasma(From enrollment to the end of treatment at 3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Joseph Quinn

OHSU Parkinson Center Director

Oregon Health and Science University

研究点 (1)

Loading locations...

相似试验